ABSTRACT
Objective To analyze the use of antidepressants and its influencing factors in patients with depressive disorders in Haikou City,and to provide some reference for clinical rational drug use.Methods 310 patients with depressive disorder in Haikou were selected.All patients were assessed with the selfdesigned General Situation and Drug Use Questionnaire,General Self-efficacy Scale (GSES),Quality of Life Questionnaire for Psychiatric Patients (QOL-P) and Hamilton Depression Scale (HAMD-17).Results (1)The usage rate of serotonin reuptake inhibitors (SSRIs) was 53.22％,30.32％ for tricyclic antidepressants (TCAs) and 16.45％ for other new antidepressants.(2)Patients'self-efficacy (β=-0.473,OR=0.713,P=0.030),social function (β=0.371,OR=1.437,P=0.036),family income (β=-1.242,OR=0.423,P=0.001) were the factors influencing patients' choice of TCAs;family income (β=-1.762,OR=0.234,P=0.001),payment method (β =0.248,OR =1.157,P =0.030) were the factors influencing the choice of SSRIs drugs;self-efficacy (β=0.563,OR=1.913,P=0.041) and depression (β=0.543,OR=2.225,P=0.026) were the factors influencing the choice of other new antidepressants.Conclusion Traditional antidepressants such as serotonin reuptake inhibitors and tricyclic antidepressants are still widely used in patients with depressive disorders.Self-efficacy,social function,income,and payment methods can influence the drug selection of depressive patients.
ABSTRACT
Objective: To explore the efficacy of evening medication of amlodipine combining valsartan on blood pressure (BP) and renal function in patients with abnormal nocturnal blood pressure. Methods: A total of 87 abnormal nocturnal BP patients without ideal efficacy by 4 weeks amlodipine therapy were randomly divided into 2 groups: Control group, based on amlodipine therapy, the patients received morning valsartan (80-160) mg, qd, n=43 and Observation group, based on amlodipine therapy, the patients received evening valsartan (80-160) mg, qd, n=44. All patients were treated for 8 weeks. Pre- and post-medication BP at day and night were observed by 24h ambulatory BP monitoring, the renal function was measured and the incidence of adverse events was recorded. Results: In Observation group: compared with pre-medication, the average day and night systolic BP (SBP) and diastolic BP (DBP) were decrease at post-medication; compared with Control group, Observation group had the lower night SBP and DBP, P0.05. Conclusion: Evening medication of amlodipine combining valsartan may effectively control night BP and improve renal function in patients with abnormal nocturnal BP; it didn't elevate the incidence of adverse events.
ABSTRACT
Objective To evaluate the clinical value of endoscopically nasojejunal feeding tube placement (ENFTP) for nutritional support in patients with severe acute pancreatitis (SAP). Methods Those SAP patients who treated with ENFTP (n= 47) or with total parenteral nutrition (TPN) (n=50) were retrospectively analyzed for laboratory parameters before and 1,2 and 4 weeks after nutrition support. Outcomes in the two groups were compared with respect to complications,mortality, duration of feeding, feeding costs,mechanical ventilation time and length of ICU or hospital stay. Results Four weeks after nutrition sypport, the hemoglobin and albumin were increased in ENFTP group as compared to TPN groups (P < 0. 05), while the blood sugar was decreased significant in ENFTP group than in TPN group (P<0.05). The incidence of peripancreatic or biliary infection and catheter-related infection were lower in ENFTP group than in TPN group. Duration of feeding and hospital stay were shorter, and nutrition cost was lower in ENFTP group (P<0.05). In addition, the APACHE Ⅱ score was significantly improved in ENFTP group(P<0.05). Conclusion ENFTP seems to be safe and less expensive in treatment of patients with acute pancreatitis.
ABSTRACT
Objective To investigate the expressions of FAT10 and p53 mutant in gastric cancer tissues and their relations. Methods Immunohistochemistry and RT-PCR were used to detect the expressions of FAT10 and p53 in gastric cancer tissues (n=62), para-cancerous tissues (2-5 cm apart from cancer, n=62), and normal gastric tissues (7>5 cm apart from cancer, n=62). The association of FAT10 with p53 and clinical outcomes were analyzed by Spearman and Pearson correlation. Results The immunohistochemistry examination showed that expressions of FAT10 [51.61%(32/62)] and p53 [45.16% (28/62)] were significantly higher in cancerous tissues than in para-cancerous tissues [12.90%(8/62) and 14.51% (9/62), χ2=21.26 and 20.69, P<0.01] and normal tissues [6.45% (4/62) and 9.68% (6/62), χ2=13.91 and 19.61, P<0.01]. Overexpressions of FAT10 protein and mRNA in cancerous tissues were closely related to lymph node metastasis and TNM staging (both P value<0.05). There was a positive correlation between FAT10 and p53 in protein and mRNA expressions (protein r=0. 865, P<0.05; mRNA r=0.761, P< 0.01). Those with positive expression of FAT10 had lower survival rate compared to those with negative expression (P<0.05). Conclusions The positive relation between over-expression of FAT10 and p53 implicates that both are involved in the gastric carcinogenesis, and FAT10 is a novel gastric cancer marker with prognostic significance.